Source comparison
Quick Comparison Table
Origin. BPC-157 is a synthetic 15-amino-acid peptide derived from a human gastric juice protein (1,419 Da). KPV is a synthetic tripeptide (Lys-Pro-Val) from positions 11 to 13 of alpha-MSH (342.43 g/mol). Primary mechanism. BPC-157 works through angiogenesis v
This comparison does not assign a generated winner or score.
- Origin. BPC-157 is a synthetic 15-amino-acid peptide derived from a human gastric juice protein (1,419 Da). KPV is a synthetic tripeptide (Lys-Pro-Val) from positions 11 to 13 of alpha-MSH (342.43 g/mol).
- Primary mechanism. BPC-157 works through angiogenesis via VEGFR2, nitric oxide synthesis, growth hormone receptor upregulation, and ERK1/2 signaling. KPV works through NF-kB inhibition via IkB-alpha stabilization, MAPK suppression, and PepT1-mediated intracellular uptake.
- Primary use. BPC-157 targets structural tissue repair — GI mucosa, tendons, ligaments, and muscle — as well as gastroprotection. KPV targets anti-inflammatory conditions including IBD, colitis, dermatitis, and bronchial inflammation.
- Gut-specific advantage. BPC-157 is stable in gastric acid and promotes mucosal repair and angiogenesis in GI tissue. KPV is preferentially taken up by inflamed colonic tissue via the PepT1 transporter.
- Oral viability. Both are orally viable. BPC-157 survives gastric acid. KPV is actively transported via PepT1.
- Typical dose. BPC-157: 250 to 500 mcg per day orally or subcutaneously. KPV: 500 to 1,500 mcg per day orally, or 200 to 500 mcg per day subcutaneously.
- Research volume. BPC-157 has extensive research — over 100 preclinical studies and 3 small human pilots. KPV has moderate research volume with key studies in colitis, IBD, and dermatitis; no human trials have been completed.
- Regulatory status. BPC-157 is not FDA-approved and is a Category 2 bulk drug substance. KPV is not FDA-approved but is potentially moving toward Category 1 compounding eligibility. BPC-157 is explicitly prohibited by WADA under S0 since 2022. KPV is likely prohibited under WADA's S0 blanket ban on unapproved substances.